dc.contributor.author | Bello, Shaibu Oricha | |
dc.contributor.author | Yunusa, Abdulmajeed | |
dc.contributor.author | Igumbor, Ehimario Uche | |
dc.date.accessioned | 2023-04-20T13:16:35Z | |
dc.date.available | 2023-04-20T13:16:35Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Bello, S. O. et al. (2023). Innovative, rapid, high-throughput method for drug repurposing in a pandemic—A case study of SARS-CoV-2 and Covid-19. Frontiers in Pharmacology, 14, 1130828. https://doi.org/10.3389/fphar.2023.1130828 | en_US |
dc.identifier.issn | 1663-9812 | |
dc.identifier.uri | https://doi.org/10.3389/fphar.2023.1130828 | |
dc.identifier.uri | http://hdl.handle.net/10566/8849 | |
dc.description.abstract | Several efforts to repurpose drugs for COVID-19 treatment have largely either
failed to identify a suitable agent or agents identified did not translate to clinical
use. Reasons that have been suggested to explain the failures include use of
inappropriate doses, that are not clinically achievable, in the screening
experiments, and the use of inappropriate pre-clinical laboratory surrogates to
predict efficacy. In this study, we used an innovative algorithm, that
incorporates dissemination and implementation considerations, to identify
potential drugs for COVID-19 using iterative computational and wet
laboratory methods. The drugs were screened at doses that are known to
be achievable in humans. Furthermore, inhibition of viral induced cytopathic
effect (CPE) was used as the laboratory surrogate to predict efficacy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Media | en_US |
dc.subject | Covid-19 | en_US |
dc.subject | Public health | en_US |
dc.subject | Drugs | en_US |
dc.subject | Pharmacology | en_US |
dc.title | Innovative, rapid, high-throughput method for drug repurposing in a pandemic—A case study of SARS-CoV-2 and Covid-19 | en_US |
dc.type | Article | en_US |